What is the Fiscal Year for Citius Oncology?
Date: November 13, 2026
Citius Oncology's current fiscal year starts on October 1, 2026, and ends on September 30, 2027. Their current quarter is Q1, which ends on December 31, 2026.
Current Fiscal Year Overview
Fiscal Year Start
October 1, 2026
Fiscal Year End
September 30, 2027
Current Quarter
Q1
Current Quarter End
December 31, 2026
Quarterly Breakdown
Q1
Oct 1, 2026 – Dec 31, 2026
Q2
Jan 1, 2027 – Mar 31, 2027
Q3
Apr 1, 2027 – Jun 30, 2027
Q4
Jul 1, 2027 – Sep 30, 2027
Company Information
Headquarters
Cranford, New Jersey
Industry
Pharmaceutical Manufacturing
Stock Symbol
CTOR
Description
Citius Oncology, Inc. (Nasdaq: CTOR) is a platform to develop and commercialize novel targeted oncology therapies. In August 2024, its primary asset, LYMPHIR, was approved by the FDA for the treatment of adults with relapsed or refractory CTCL who had had at least one prior systemic therapy. Management estimates the initial market for LYMPHIR currently exceeds $400 million, is growing, and is underserved by existing therapies. Robust intellectual property protections that span orphan drug designation, complex technology, trade secrets and pending patents for immuno-oncology use as a combination therapy with checkpoint inhibitors would further support Citius Oncology’s competitive positioning. Citius Pharmaceuticals (Nasdaq: CTXR) owns approximately 90% of Citius Oncology.
Use Salesmotion for Account Data and Insights
Sales professionals can use Salesmotion to access comprehensive account intelligence and automate their research. Instantly get insights on companies like Citius Oncology and uncover key business information that drives smarter conversations.
Book a demo today to strengthen your sales strategy with powerful data and actionable insights.